Also known as: Xinermei, IBI362
A GLP-1 and glucagon dual agonist approved in China for obesity and type 2 diabetes.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Combines appetite reduction (GLP-1) with higher energy use and liver fat burning (glucagon).
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Fat loss & weight | B | Human trials (smaller, mixed, or approved outside the US) |
| Blood sugar & metabolic | B | Human trials (smaller, mixed, or approved outside the US) |
At a glance
- Route
- Subcutaneous weekly
- Half-life
- About 1 week
Reported dosing
Weekly, escalated per the Chinese label.
Timing: Same day each week.
Cycle: Long-term.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- GI effects
- Raised heart rate
Who should avoid it
- GLP-1 class warnings
Often combined with
Used alone.
Key findings
Chinese Phase 3 trials supported approval; Phase 3 is ongoing elsewhere.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Approved in China (2025) only.
Sources
Open Mazdutide in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.